DVM

Bango PLC ("Bango" or the "Company") 2023 Full Year Results and 2024 Outlook

Retrieved on: 
Monday, April 8, 2024
Annual, DVM, Growth, ARR, NHN Entertainment Corporation, Digital, Wind, Investment, Annual report, The Annual Report, Depreciation, Music, BST, NHN, Video game

And, to transfer the technology developed in the joint venture to Bango and NHN so both can use it without restriction in their respective core businesses.

Key Points: 

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA

Retrieved on: 
Monday, April 8, 2024
Arthralgia, Osteoarthritis, DVM, Mayra Andrade, Hip, Patient, Synovial joint, Pain management, ACVS, Limp, Quality of life, Trial of the century, Dog, JW Marriott Hotels, JW Marriott Indianapolis, Joint, Pain, CCRT, VOS, Animal, CCD, Poultry farming

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/
    Pain Management Forum Exhibit Details:
    Location: The JW Marriott in Indianapolis, Indiana
    Presentation Title: How do we Elevate Our Strategy for Managing Osteoarthritis in Pets?

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Retrieved on: 
Wednesday, March 27, 2024
Transforming growth factor beta, Eli Lilly, Atrophy, DVM, Obesity, Drug discovery, Exercise, Partnership, Patient, SAN, EDT, Learning, Entrepreneurship, IND, Antibody, Drug development, PIPE, Pharmaceutical industry

BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.

Key Points: 
  • Yesterday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional investors.
  • The company will use a portion of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
  • The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio’s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise.
  • iBio has the exclusive option to license three (3) cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.

iBio Announces $15.0 Million Private Placement

Retrieved on: 
Tuesday, March 26, 2024
DVM, Exercise, Act, SAN, Research, Sale, Security (finance), United, PIPE, Regulation D

BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement agent fees and offering expenses.
  • The fully subscribed PIPE financing included participation from ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional and accredited investors.
  • The Company intends to use the net proceeds from the offering for general corporate purposes, including research and development and working capital.
  • The Company also expects the net proceeds will extend its cash runway to fund its operating plan through fiscal year 2025.

Chasing Our Tails: Get Joy Unveils Startling Findings in Dog Wellness and Nutrition Survey

Retrieved on: 
Thursday, April 4, 2024
Pets, Consumer, Socialization, Overweight, Health, DVM, Obesity, Longevity, Prevalence, Exercise, Nutrition, Probiotic, Diabetes, Education, Knowledge, Perception, Sleep, Holism, Research, Cancer, Food, Overalls, Dog, Diet, Joy, Wellness, Research report, Pet, Multimedia, Family, Parent, Pet industry

Get Joy , a pioneer in holistic dog wellness, is unveiling a new research report titled "Chasing our Tails: When it Comes to Maximizing our Dog’s Health and Wellness, Are We Just Running in Circles?"

Key Points: 
  • Get Joy , a pioneer in holistic dog wellness, is unveiling a new research report titled "Chasing our Tails: When it Comes to Maximizing our Dog’s Health and Wellness, Are We Just Running in Circles?"
  • Tom Arrix, founder and CEO of Get Joy, identifies with this paradox, stating “My life took a profound turn when our family dog Cooper battled lymphoma.
  • In light of these findings, Get Joy urges dog owners to reassess their approach to nutrition and prioritize fresh, whole foods that promote gut health.
  • Get Joy is committed to further research and advancing canine wellness through education and advocacy, empowering dog owners with the knowledge and resources they need.

The American College of Veterinary Internal Medicine Partners with MentorVet and Chewy Health to Launch Mentorship Program for New Diplomates

Retrieved on: 
Monday, March 25, 2024
Education, Health, Consumer, Pets, University, Veterinary, DVM, Partnership, Patient, Mental health, Oncology, American College, Pet, Nursing

The American College of Veterinary Internal Medicine (ACVIM) and MentorVet have partnered to deliver a new mentorship program: MentorVet Lead for New Diplomates.

Key Points: 
  • The American College of Veterinary Internal Medicine (ACVIM) and MentorVet have partnered to deliver a new mentorship program: MentorVet Lead for New Diplomates.
  • Importantly, participants will have access to individualized mental health and financial coaching, as well as one-on-one mentorship with more established ACVIM Diplomates.
  • MentorVet Lead is the result of collaboration between ACVIM, Chewy Health, and MentorVet, an organization that uses evidence-based approaches to empower veterinary professionals.
  • “At Chewy Health, we are passionate about providing veterinary professionals with access to the education and resources they need to thrive in practice," said Mita Malhotra, President of Chewy Health.

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Monday, March 11, 2024
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Clinical Trials, DVM, Survival, Göttingen, Ophthalmology, Doctor of Philosophy, Therapy, RPE

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 ( OpRegen ) will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO) .

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 ( OpRegen ) will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO) .
  • The meeting will be held May 5-9, 2024, in Seattle, WA.
  • The presentation, “OpRegen engrafts within the retinal pigmented epithelium (RPE) of Gottingen mini-pigs by 4-weeks post-administration via subretinal delivery,” will be presented by Rachel N. Andrews, DVM, PhD, DACVP, Principal Scientist-Pathologist, Safety Assessment, Genentech, a member of the Roche Group, on behalf of Roche and Genentech .

VCA Animal Hospitals, Proudly Part of Mars Veterinary Health, Recognized as one of America's Greatest Workplaces for Diversity for 2024 by Newsweek

Retrieved on: 
Thursday, April 4, 2024
Hospital, VCA Animal Hospitals, HR, Culture, DVM, Associate, Patient, Diversity, Equity, Organization, VCA, EI, Love, Animal, Nursing

LOS ANGELES, April 4, 2024 /PRNewswire/ -- VCA Animal Hospitals, the global leader of comprehensive veterinary services and proudly part of Mars Veterinary Health, is honored to announce it has been recognized by Newsweek as one of America's Greatest Workplaces for Diversity for 2024.

Key Points: 
  • LOS ANGELES, April 4, 2024 /PRNewswire/ -- VCA Animal Hospitals, the global leader of comprehensive veterinary services and proudly part of Mars Veterinary Health, is honored to announce it has been recognized by Newsweek as one of America's Greatest Workplaces for Diversity for 2024.
  • This ranking highlights VCA's commitment to equity, inclusion and diversity (EI&D), and underscores how diverse teams thrive and deliver the best care for patients and clients.
  • This Newsweek recognition quickly follows VCA Canada's recent accomplishment of being honored with the prestigious title of one of Alberta's Top Employers for 2024.
  • For more information about Newsweek's list of America's Greatest Workplaces for Diversity for 2024 and to see VCA's ranking, click here .

Service and Working Animals Receive Free Eye Exams Across the U.S.

Retrieved on: 
Tuesday, April 2, 2024
Service animal, DVM, Veterinary medicine, Working animal, Human, Veterinarian, City, American College, Animal, Paratriathlon, Pain, Multimedia, Ophthalmology, Nursing

MERIDIAN, Idaho, April 2, 2024 /PRNewswire/ -- The American College of Veterinary Ophthalmologists® (ACVO) is proud to announce registration opens for the 15th annual National Service Animal Eye Exam Event, sponsored by Epicur Pharma®, April 1 to 30, 2024. The event brings together more than 250 board-certified ACVO Diplomates across approximately 170 cities in the U.S.A., Canada, Hong Kong, Puerto Rico, and the United Kingdom to provide screening free eye exams to Service and Working Animals in May. Appointment availability can be limited and must be made by Service and Working Animal handlers during the registration period from April 1st to 30th, 2024.

Key Points: 
  • The event brings together more than 250 board-certified ACVO Diplomates across approximately 170 cities in the U.S.A., Canada, Hong Kong, Puerto Rico, and the United Kingdom to provide screening free eye exams to Service and Working Animals in May.
  • Appointment availability can be limited and must be made by Service and Working Animal handlers during the registration period from April 1st to 30th, 2024.
  • "The ACVO/Epicur National Service Animal Eye Event is one that my colleagues and I look forward to all year.
  • To qualify for a free eye exam, animals must be active, currently working, formally trained Service, Working, or formally trained therapy animals (with written proof of therapy training & registration).

Nonprofit Companion Animal Parasite Council (CAPC) Warns Parasitic Pet Diseases Will Spread Further in 2024

Retrieved on: 
Tuesday, April 2, 2024
Parasitism, Temperature, Health, Prevalence, DVM, Forecasting, Lyme disease, Disease, Incidence, Coccidioides immitis, Risk, Florida College, Parasitic disease, Tick, Research, Notifiable disease, Anaplasmosis, University, Companion Animal Parasite Council, CAPC, Doctor of Philosophy, Ehrlichiosis, Veterinarian, Human, MBA, Infection, CDC, Veterinary medicine, Population density, Vaccine, Animal, Family, Movement, Weather

SALEM, Ore., April 2, 2024 /PRNewswire-PRWeb/ -- The nonprofit Companion Animal Parasite Council (CAPC), the nation's leading authority on parasitic diseases that threaten the health of pets and people, today warned of the continued expansion of heartworm, Lyme Disease and other tick-borne diseases throughout the United States in 2024. Pet owners can learn more about higher-than-average parasitic disease risks CAPC predicts in its 2024 Pet Parasite Forecast released today, as well as in its corresponding monthly prevalence maps at petdiseasealerts.org.

Key Points: 
  • Pet owners can learn more about higher-than-average parasitic disease risks CAPC predicts in its 2024 Pet Parasite Forecast released today, as well as in its corresponding monthly prevalence maps at petdiseasealerts.org .
  • While CAPC's nationwide annual forecasts track progression of diseases, our monthly forecasts at petdiseasealerts.org help pet owners understand immediate threats in their neighborhoods.
  • In its 2024 Pet Parasite Forecast , CAPC reports ticks and mosquitoes remain the principal transmitters of pet and human vector-borne diseases.
  • Both the annual forecast and the 30-Day Pet Parasite Forecast Maps are designed to alert pet owners of impending outbreaks.